On August 25, Twist Bioscience Corp rose 5.03% in regular trading, trading at $147.845/share, with turnover of $9.25 million, staging a strong rebound after declining 5.58% in the prior session.

On the news front, the company disclosed on August 20 that it was selected by Anthropic as an independent evaluator for a multi-arm AI protein design project. Twist Bioscience is responsible for rapidly producing AI-designed proteins at scale and testing their binding capabilities. Anthropic is utilizing Claude Opus 4.8 and Mythos Preview to conduct protein design experiments targeting 15 different targets. The role as an external evaluator further solidifies Twist Bioscience's position as a core supplier in the AI-driven drug discovery supply chain, specifically in DNA synthesis and protein production.

Since the announcement, shares have surged over 27% from pre-announcement levels, reflecting strong investor enthusiasm for AI-biology convergence opportunities. The company also previously guided fiscal Q4 revenue of $123M-$124M, above the FactSet estimate of $117.4M, providing additional fundamental support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)